Full Press Release Details
IDEAYA Biosciences Announces Acquisition of Proprietary INQUIRE TM Chemical Library to Enhance Synthetic Lethality Drug Discovery Platform.
IDYA
IDEAYA Biosciences Announces Acquisition of Proprietary INQUIRE TM Chemical Library to Enhance Synthetic Lethality Drug Discovery Platform
Key Takeaway: IDEAYA Biosciences Announces Acquisition of Proprietary INQUIRE TM Chemical Library to Enhance Synthetic Lethality Drug Discovery Platform
Price reaction · baseline $22.31 (2022-01-04 close) · hit after-hours · 1 other IDYA headline(s) in the window, move may be shared
day 0 close
-9.4%
day 1
-10.7%
day 3 · peak
-22.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma